Guide to Hepatitis B for People Living With HIV

Section 4: HBV Disease Progression and the Impact of HIV Coinfection

One of the most perplexing aspects of HBV infection is its disease progression. In fact,
researchers still don't fully understand why some people with HBV have no associated health
problems, while others progress to serious liver disease; however, we do know that HBV
disease progression is driven by the immune system's ability to control HBV replication, and
that damages to the liver result from this dynamic process.

Chronic HBV disease progression varies widely among individuals, but in general there are
four distinct disease phases. Not everyone will go through every phase, and there can be
fluctuations and reversions.

Phase 1: Immune Tolerant

During this phase, HBV is infecting liver cells and replicating at a very high
rate, but the immune system either does not recognize the infection or is
incapable of mounting an effective defense -- the immune system is tolerating
the virus. Since there is little-to-no immune response, the risk of liver damage is
very low, and treatment is not recommended.

Primarily seen in people infected at birth or in early childhood, the immune
tolerant phase can last decades, so most people can remain in this phase until
their twenties and thirties. People infected as adults usually will not have an
obvious immune tolerant phase.

The impact of HIV infection on the immune tolerant phase is not clear. Since
HIV disease progresses faster than HBV-related liver damage can develop, the
immune tolerant phase will not make a difference in treatment decisions in
HIV/HBV coinfection.

Phase 2: Immune Clearance

Researchers are still not sure what triggers the immune system to activate and
attempt to control a previously unnoticed HBV infection, but when it does, the
immune-clearance phase has begun. During this phase, the immune system
and HBV battle for control. The amount of virus in the body will rise and fall
in response to the intensity of the immune activation. This phase can last from
years to decades, primarily in people younger than 35, during which time liver
damage can develop. Because of the risk of liver damage, people in
the immune clearance phase are often recommended to go on treatment.

During immune clearance, HIV-positive people have more HBV in the body
than people without HIV; at the same time, their immune responses to HBV
are less intense. This makes it harder for them to clear HBV infection without
treatment. As a result, they are more likely to remain in the immune clearance
phase for a longer period of time. As their weakened immune systems attempt
to control HBV repeatedly and without success, causing low but persistent liver
inflammation, HIV-positive people are more likely to develop serious liver
damage during the immune clearance phase.

Phase 3: Inactive

When the immune system is able to gain the upper hand, people with HBV will
pass into an inactive disease phase. There may still be some very low-level HBV
replication, but it will elicit little or no immune response and will not cause liver
damage. Chronic HBV is considered to be in remission. In some people,
especially those who did not develop liver damage during the immune
clearance phase, HBV stays in remission indefinitely; nonetheless, those people
still have a low risk of developing liver cancer as they age, possibly because of
previous liver damage or other unknown effects of prolonged HBV infection.

Since the inactive phase is dependent on immune control of HBV, immune
suppression caused by HIV will upset this balance. As HIV disease progresses,
people will likely lose the ability to control HBV. HIV-positive people are unlikely
to stay in remission without treatment and may revert to the immune clearance
phase or progress to the next phase: reactivation.

Phase 4: Reactivation

Chronic HBV can reactivate in some people after a period of inactivity. This
generally starts to occur as men reach the age of 40 and women reach the
age of 50 who have been infected at birth, and the likelihood of reactivation
increases as they get older. Researchers believe this is caused by the combined
effects of the loss of immune function associated with aging, and naturally
occurring HBV mutations (in the pre-core or basal-core regions of the viral
genome). As the weakened immune system cannot recognize and sufficiently
control these HBV mutations, more viral replication follows.

Another type of reactivation is seen in people who have cleared HBV either
spontaneously or with treatment. This can happen when the immune system
is affected by chemotherapy, high-dose steroids, or other immunosuppressive
therapies such as those commonly used during bone-marrow and stem-cell
transplantation. Rarely, people have become infected with HBV after liver
transplantation with an organ from a previously infected donor, even when
the donor had cleared HBV spontaneously.

Reactivation can be more severe in HIV-positive people and rapidly cause
serious liver damage. It is also possible for HBV to reactivate in HIV-positive
people who have spontaneously cleared HBV in the past. As immune function
often fluctuates in HIV disease, repeated episodes of reactivation are more
likely in HIV/HBV coinfection; these can cause more liver scarring, speed up
liver damage, and lead to a higher rate of developing cirrhosis. It is difficult to
provide a more precise risk ratio of liver damage in HIV/HBV coinfection, since
the availability of treatment has largely been effective in halting HBV disease
progression.

The Body is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.